Characterization Of A Parp Inhibitor Biomarker For Cancer Therapy

Characterization of a PARP Inhibitor Biomarker for Cancer Therapy (AACR)

GenScript USA Inc.

Identification and Characterization of a Novel Biomarker for Cancer Therapy

GenScript USA Inc.

Biomarker for PARP inhibitor responsiveness in ovarian cancer patients

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors

Biomarkers of PARP Inhibitors in Cancers and Beyond

MD Cigarette Restitution Fund

Maintenance Therapy: PARP Inhibitor or Bevacizumab

Biomarker analysis of olaparib with or without cediranib in mCRPC

Stratification in Cancer Medicine - Matthew Garnett

Wellcome Connecting Science Learning and Training

Molecular Classification of Endometrial Cancer and Targeted Therapy Considerations

LurieCancerCenter

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches

PeerView Oncology

Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer

Predictive Biomarkers in Ovarian Cancer

Ongoing Clinical Trials with PARP Inhibitors in Ovarian Cancer

New Checkpoints and Biomarkers

Biomarkers to help predict response to CDK4/6 inhibitors

Biomarker analysis and updated results from PROpel

Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer

Predictive biomarkers for RAS-wt mCRC treated with cetuximab and m-FOLFOXIRI

Dr. Patel on an Analysis of Olaparib and Cediranib for Ovarian Cancer

Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology

PeerView Oncology